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ABSTRACT
Objective: To analyze the protective effect of Vitamin E on cisplatin toxicity in Sprague Dawley mice nephrons. Material & 
Methods: This is an experimental study using post-test only control group design, the subject was white male mice (Rattus 
Norvegicus) adult Sprague Dawley strain  (10-12 weeks) of 24 rats divided into four groups. Negative control group (CN) 
got normal saline 0.9% intraperitoneal 1 cc, Positive control group (CP) got cisplatin 5 mg/kgBB, group P1 got vitamin E 
50 mg/kgBB and Cisplatin 5 mg/kgBB, and P2 group got vitamin E 200 mg/kgBB plus cisplatin 5 mg/kgBB intraperitoneal. 
Cisplatin is conducted in the third week in each treatment group through intraperitoneal injection. Vitamin E                      
is administrated per sonde for the first three weeks resumed on the fourth week to the seventh week. At the end of the seventh 
week, nephrectomy was performed on the treatment group to analyze the kidney damage. Histopathological observation is 
performed using a light microscope with a magnification of one hundred and four hundred times magnification. Results: 
Cisplatin administration resulted in significant tubular and glomerular damage compared to the control group. Increasing 
the dose of vitamin E in mice that received cisplatin resulted in significant nephron damage compared to the group who 
received cisplatin alone. Conclusion: Cisplatin administration results in nephrotoxicity in mice. The administration of high 
dose Vitamin E resulted in increased nephrotoxicity in mice that received cisplatin. 
Keywords: Cisplatin, vitamin E, glomerulus, kidney tubules, nephrotoxicity.
ABSTRAK
Tujuan: Menganalisis kemampuan proteksi isomer vitamin E pada nefron tikus Sprague Dawley yang terpapar ciplatin. 
Bahan & Cara: Penelitian ini merupakan studi eksperimental laboratorium dengan post test only control group design, 
subjek penelitian adalah tikus putih jantan (Rattus Norvegicus) jenis Sprague-Dawley (10–12 minggu) sejumlah 24 ekor 
terbagi dalam empat kelompok. Kelompok kontrol negatif (CN) mendapatkan normal saline 0.9% intra peritoneal 1 cc, 
kelompok kontrol positif (CP) mendapatkan Cisplatin 5 mg/kgBB,  kelompok P1 mendapatkan vitamin E 50 mg/kgBB dan 
Cisplatin 5 mg/kgBB, dan kelompok P2 mendapatkan vitamin E 200 mg/kgBB ditambah cisplatin 5 mg/kgBB intra 
peritoneal. Pemberian cisplatin dilakukan di minggu ketiga pada tiap kelompok perlakuan melalui injeksi intraperitoneal. 
Vitamin E diberikan per sonde selama tiga minggu pertama dilanjutkan pada minggu keempat hingga minggu ketujuh.  
Diakhir minggu ketujuh, nefrektomi dilakukan pada kelompok perlakuan untuk dilakukan analisa kerusakan ginjal. 
Pengamatan histopatologi dilakukan menggunakan mikroskop cahaya dengan pembesaran seratus dan empat ratus kali. 
Hasil: Cisplatin mengakibatkan kerusakan tubulus dan glomerulus ginjal secara signifikan dibandingkan dengan 
kelompok kontrol. Peningkatan dosis vitamin E pada tikus yang mendapatkan cisplatin mengakibatkan terjadinya 
kerusakan nefron secara signifikan dibandingkan dengan kelompok yang mendapatkan cisplatin saja. Simpulan: Cisplatin 
mengakibatkan terjadinya nefrotoksisitas pada tikus. Pemberian Vitamin E dengan dosis tinggi mengakibatkan terjadinya 
peningkatan nefrotoksisitas pada tikus yang mendapatkan cisplatin.  
Kata Kunci: Cisplatin, vitamin E, glomerulus, tubulus ginjal, nefrotoksisitas.
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THE EFFECT OF VITAMIN E (α-TOCOPHEROL) ADMINISTRATION        
ON GLOMERULUS AND PROXIMAL KIDNEY TUBULES DAMAGE WHICH 
RECEIVED CISPLATIN EXPOSURE ON SPRAGUE DAWLEY MICE
INTRODUCTION
One of the most effective antineoplastic 
drugs and is most often used as a chemotherapy 
agent for cancer today is Cisplatin. Cisplatin works 
by inhibiting deoxyribonucleic acid (DNA) 
replication by forming the interstrand crosslinks 
with DNA. The Clinical use of cisplatin has been 
88
shown to successfully provide a better prognosis and 
reduce the mortality rates of cancer patients. But the 
greater the dose of cisplatin, the more severe the side 
1 
effects are inflicted.
Nephrotoxicity is a side effect of cisplatin 
which needs special attention and treatment. Induced 
nephrotoxicity due to the use of cisplatin can lead to 
2
decreased kidney function and is permanent.  
Recently, the pathophysiology of cisplatin nephro-
toxicity has been focusing on the understanding of 
cellular and molecular mechanisms. Tubular cell 
exposure to cisplatin will activate complex signaling 
pathways that cause damage and death from tubular 
cells. Meanwhile, many inflammatory responses are 
stimulated which will cause impairment in kidney 
tissue. Cisplatin was also known to induce 
impairment in renal vascularization so that it will 
ultimately reduce blood flow and ischemic damage 
from the kidneys, which contributes to a decrease in 
glomerular filtration (GFR). This results in loss of 
kidney function in the cephiloxic cisplatin process 
and triggers kidney failure. 
Oxidative stress such as reactive oxygen 
species (ROS) has been shown to be a significant 
3
factor in cisplatin nephrotoxicity.  Some mecha-
nisms regarding the role of ROS in this pathological 
condition are this substance causing accumulation of 
ROS and oxidative stress cells which can continue to 
mitochondrial dysfunction and increased the 
production of ROS through a disrupted respiratory 
chain. A rise of reactive oxygen species (ROS) was 
successfully observed when cisplatin was exposed to 
renal tubular cell cultures, kidney fragments, and in 
4,5
all parts of animals in vivo.  ROS directly act 
molecular components of cell including lipids, 
6
proteins and DNA and damage their structure.  In the 
presence of cisplatin, ROS is produced and involved 
in the pathogenesis of cisplatin-induced kidney 
7
damage.
Vitamin E is a fat-soluble vitamin and is 
included in non-enzymatic antioxidants. Vitamin E 
prevent or reduce the cell damage caused by 
oxidative stress by preventing the occurrence of fat 
8
peroxidation reactions by ROS in membrane cells.  
Oral supplementation of vitamin E is known to be 
effective in lowering the incidence and severity of 
9
cisplatin-induced nephrotoxicity.  It is important to 
know that natural products from antioxidants may 
detoxify ROS in the kidneys, without affecting the 
anticancer efficacy of cisplatin, even though the 
active ingredients still remain unknown, but the 
protective effects on kidneys have been proven to be 
true in humans and vitamin E may have potential 
therapeutic applications.
OBJECTIVE
To analyze the role of vitamin E α-
tocopherol on cisplatin toxicity in Sprague Dawley 
mice kidney. 
MATERIAL & METHODS
This research is a laboratory experimental 
study with post-test only control group design. The 
subjects of the study were Sprague Dawley white 
male rats aged 10-12 weeks old with a weight of 200-
250 grams. This study has obtained ethical approval 
with a registration number 2.KE.027.02.2019.
24 white male rats were obtained from the 
integrated research institute of Gadjah Mada Uni-
versity (UGM) Yogyakarta. Experimental animal 
acclimatization was carried out for two weeks before 
being given treatment with exposure to a dark-light 
irradiation cycle of 12 hours for each group. Mice are 
2
kept in cages with a size of 1600 cm  at room 
temperature and regular air circulation. Food in the 
form of pellets is given as much as 20-25 grams per 
day with clean water that is always available. 
The process of animal grouping was 
randomly assigned into four treatment groups, 
namely: negative control group (CN) which received 
normal saline injection treatment 0.9% 1 cc 
intraperitoneal, positive control group (CP) received 
cisplatin injection (Cisplatin, Kalbe Farma, 
Indonesia) intraperitoneal with a dose of 5 mg/kg, 
group P1 was given vitamin E (Blackmores, 
Australian Catalent) 50 mg/kg per Sonde for 7 weeks 
combined with injection of cisplatin 5 mg/kg 
intraperitoneal, P2 group was given vitamin E 
treatment (Blackmores, Catalent Australia) 200 
mg/kg per Sonde for 7 weeks combined with 
injection of cisplatin (Cisplatin, Kalbe Farma, 
Indonesia) 5 mg/kg. Cisplatin exposure in each 
treatment group was carried out in the third week 
with an intraperitoneal injection route.  
th
At the end of the 7  week of treatment, each 
experimental animal was sacrificed to analyze the 
degree of kidney damage. Anesthesia in 
experimental animals was carried out using 75 
mg/kg intraperitoneal ketamine. After anesthesia, 
the mouse was positioned supine. The mice were 
fixed on the fixation board for layer by layer 
incisions to make the kidney visible. Arteries and 
veins around the kidney are clamped before the 
action is continued with nephrectomy. The rest of 
experimental animals and unused organs will be 
destroyed. 
The method for examining histological 
changes in this preparation is using the modified 
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Klopfleisch (2013) method. Observations were 
made on the glomerulus and proximal tubules. 
Observations were performed at 100 and 400 times 
magnification using a light microscope. At 100 times 
magnification, observation is focused on seeing 
tubular dilatation and glomerular damage lesions. 
Meanwhile, at 400 times magnification, the 
observation is focused on assessing the presence of 
tubular degeneration, tubular necrosis, and 
interstitial inflammatory cell infiltration. Kidney 
damage scoring in each group is the average amount 
of all forms of occurred lesions. All scoring 
examinations use the Olympus CX21 light 
microscope, taking pictures to use a Nikon H600l 
light microscope equipped with a 300 megapixel DS 
Fi2 digital camera and Nikkon Image System 
graphics processing software.
 Data obtained from observations will be 
quantified and calculated statistically by one-way 
ANOVA parametric test. If the data is not normally 
distributed, statistical analysis will be done using the 
Kruskal-Wallis non-parametric test.
RESULTS 
The normality test was carried out on the 
score of nephron damage degree obtained in each 
group. From the Shapiro Wilk normality test, the 
scores of renal nephron damage degree were 
normally distributed and each group was 
homogeneous with p>0.05 (Table 1). Then a 
comparative test was performed on the mean score of 
the nephron damage degree using the One Way 
ANOVA parametric test. The results showed a 
significant difference in the mean between study 
groups with a p<0.05 (Table 1). Data variability 
between groups was further analyzed using the 
Levene test, and there was no significant difference 
in data variance between groups with a p>0.05. 
Therefore, the LSD post hoc test was used to 
determine the difference in nephron damage in each 
treatment group. 
The result is a significant difference in 
nephron damage in all treatment groups when 
compared with the negative control group with 
p<0.05 (Table 2). Furthermore, no significant 
differences in glomerular damage were found in the 
positive control group compared to the treatment 
group which received vitamin E 50 mg/kg 
supplementation. The treatment group is also found a 
significant difference in nephron damage in the 
group that received vitamin E supplementation of 50 
mg/kg compared to the group that received vitamin E 
supplementation 200 mg/KgBB (Figure 1). 
Table 1. The effect of vitamin E on mice kidney that received cisplatin.
Group n Mean ± SD Normality p value 
Negative Control 4 3  ± 0,707 0.161 0.00* 
 Positive Control  6 6.83 ± 0,601 0.601  
Group 1  8 8.13 ± 0,611 0.425  
Group 2  8 10.75 ± 0,412  0.114  
 
CN: Control group  
CP: Cisplatin group   
P1 : Cisplatin + Vitamin E 50 mg/kgBW group
P2 : Cisplatin + Vitamin E 200 mg/kgBW group
Tabel 2. Comparison of nephron damage between groups.
Comparison of nephron damage between 
groups 
Mean 
Difference 
Confidence interval 95%
 
p value 
Lower 
bound 
Upper 
bound 
CN vs CP  -3.883* -5.79 -1.87 0.001 
CN vs P1 -5.125* -6.99 -3.26 0.000 
CN vs  P2 -7.750* -9.61 -5.89 0.000 
CP vs P1 -1.292 -2.93 0.35 0.117 
CP vs P2 -3.917* -5.56 -2.28 0.00 
P2 vs P1 -2.625* -1.11 -4.14 0.02 
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Figure 1. A Comparison of nephron damage in groups. 
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Figure 2. The results of histopathological examination using Hematoxylin Eosin (HE) staining. A and B. 
Microscopic images of dilated kidney tubules, lumen tubules enlargement is marked with star 
symbols (400X): C. Microscopic images of tubular cell degeneration, enlarged tubular cells, 
narrowed/full tubular lumen of 400X magnification: D. Microscopic images of tubular cells necrosis 
(the core appears to be picnosis), 400X magnification: E. Microscopic images of glomerular 
enlargement, the glomerulus appear large and full, marked with star symbols of 400X magnification; 
F. Microscopic images of kidneys at 200x. 
A
FE
DC
B
 
DISCUSSION
Cisplatin or commonly known as Peyronie 
chloride first synthesized in 1845 by Michele 
Peyrone. This drug was finally used against ovarian 
and testicular cancer in 1978 by the license from the 
Food and Drug Administration. Subsequently, 
cisplatin (dichlorodiamino platinum) became an 
inorganic platinum-based chemotherapy agent that 
has widely used in the treatment of various 
10
malignant solid tumors.  Until now, cisplatin has 
been used in the treatment of cancer of the testis, 
ovary, bladder, head and neck, esophagus, lung, 
breast, cervix, stomach, prostate cancer, Hodgkin 
and non-Hodgkin's lymphoma, neuroblastoma, 
sarcoma, multiple myeloma, melanoma and 
mesothelioma. Although it is famous for its 
mechanism of action damaging DNA, cisplatin also 
causes dysfunction of cytoplasmic organelles 
especially the endoplasmic reticulum and 
mitochondria. Cisplatin also activates the apoptotic 
pathway and causing cell damage through oxidative 
10,11
and inflammatory stress.
By the first time usage of cisplatin within 
2
certain doses (50-100mg/m ), about one-third of 
patients experienced nephrotoxicity. The main target 
of toxic effects by various chemical agents is the 
kidney, so drug-induced AKI (Acute Kidney Injury) 
has often found in clinical medicine. The incidence 
of nephrotoxic AKI is difficult to predict because of 
the variability in population and the criteria for AKI. 
However, nephrotoxicity has already been reported 
to suggest that cisplatin induce hospital-acquired 
12-14
AKI by 8-16%.  Renal vascular resistance, 
decreased renal plasma flow, and glomerular 
filtration (GFR) makes cisplatin nephrotoxicity an 
ideal model for studying the mechanism that induces 
15
all types of AKI.
The use of cisplatin in this study has shown 
significant glomerular damage compared to the 
control group. These results are in accordance with 
the results of previous studies, which showed that 
cisplatin has the effect of nephrotoxicity. Like the 
antineoplastic effect, cisplatin has other nephrotoxic 
effects on various parts of the nephron. The 
nephrotoxic effects are tubular damage, prolong 
5
inflammation and vascular injury.  Cisplatin enters 
kidney cells with a passive mechanism and/or 
facilitated channel. Tubular cell exposure to cisplatin 
initiates some pathways of cell death (MAPK, p53, 
ROS, etc.) or cytoprotective (p21). Cisplatin also 
known induces TNF-an expression in renal tubular 
cells, subsequently promotes inflammatory 
response, which in turn contributes to tubular cell 
injury and death. Cisplatin also causes injury to the 
renal arteries, causing ischemic tubular cell death 
and a decrease in glomerular filtration mice. Acute 
kidney failure could take place by the stimulation of 
cisplatin. There are four mechanisms of cisplatin-
induced AKI: (1) proximal tubular injury, (2) 
reactive oxidative stress (ROS), (3) inflammation 
and the last one is kidney vascular injury. Proximal 
tubular injury divide into different mechanisms 
including apoptosis, autophage, cell cycle protein 
dysregulation, activation of mitogen-activated 
protein signaling pathways (MAPK), renal tubular 
epithelial cells direct damage, DNA damage 
14
response, and mitochondrial impairment.
One of the mechanisms of AKI induced by 
cisplatin is oxidative stress. Oxidative stress defined 
as an imbalance between free radicals production 
and elimination. Subsequent generation of reactive 
oxygen species (ROS), accumulation of kidney lipid 
peroxidation residual, and the lack of antioxidant is 
considered to be the main factor of Cisplatin-induced 
16,17
AKI.  Three mechanisms have been proposed that 
can produce ROS. First, its interaction with 
glutathione during activation into stronger 
nephrotoxins depletes powerful antioxidant 
molecules cell such as glutathione. In cells, cisplatin 
is converted into a very reactive form that get rapidly 
reacted with antioxidant molecules containing tool 
such as glutathione. As a result, thinning of gluta-
thione causes an increase in oxidative stress in cells. 
Second, cisplatin also can cause mitochondrial 
dysfunction and advance further ROS production 
through disturbed respiratory chains. The third is 
cisplatin can induce ROS expression through the 
14
cytochrome P450 (CYP) system.  
Vitamin E was first discovered in 1922 by 
Evan and Bishop. Vitamin E deficiency was observed 
in pregnant mice who had syndrome deficiency, then 
impaired absorption in mice fetuses improved when 
given vegetable oil and salads. Discoveries about 
vitamin E provide greater space for structural 
18,19
exploration and function of vitamin E.  There are 2 
subclassifications of Vitamin E, namely tocopherol 
and tocoretinol. Each subclass consists of a, b, d,  and 
s. The biological and antioxidant activities of each 
subclass of vitamin E are not a coincidence, for 
example, Tocopherol which is the most partition in the 
human diet has  an antioxidant capacity 50% smaller 
than a-Tocopherol. Until now, a-Tocopherol is the 
20
most potent form of vitamin E as an antioxidant.
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Vitamin E has hydrophobic and lipophilic 
properties, so it is also known as potent lipid soluble 
antioxidant. The distribution of vitamin E in the body 
starts from the absorption process by kilomicron in 
the small intestine. Kilomicron will circulate in the 
lymph vessels that lead to the thoracic duct and join 
the circulation of Subclavian veins in the blood 
vessels. Release Vitamin E in the free form of 
kilomicron is mediated by the LPL enzyme 
(lipoprotein lipase). Remnants from kilomicron 
which have undergone release of vitamin E will be 
taken to the liver to be recycled into very low density 
lipoprotein (VLDL) or low density lipoprotein 
(LDL). Free vitamin E and its isoforms can act as 
chain-breaking antioxidants and as a deterrent to the 
formation of free radicals in the cellular 
environment. Free-form of residual vitamin E is 
usually found in very low concentrations in cell 
membranes (1:1000), but this molecule is still 
considered to play lipid soluble antioxidants in the 
21
body.
Free radicals are basically natural biological 
processes that occur in every organism. Electron 
transport that occurs between the cytochrome chains 
at each cellular respiration cycle will result in 
18
electron emissions acting as free radicals.  Unstable 
free radical molecules have an affinity for 
destabilizing stable molecules by electronic 
gradient. One free radical chain that may occur at the 
cellular level is destabilization of Polyunsaturated 
Fatty Acid (PUFA). Free radical reacts with PUFA 
will result in the formation of PUFA, which will be 
oxidized to form Polyunsaturated lipid peroxyl 
radical (PUFA-OO). The affinity of PUFA-OO for 
hydrogen, which is higher than other stable 
molecules will result in the chain transfer of 
hydrogen and electron called "free radical chain 
21
reaction".
Vitamin E in the form of T-Tocopherol 
(TocH) acts as a substance that reacts with PUFA-
OO  with the end result of hydroperoxide 
polyunsaturated fatty acids (PUFA-OOH) which is 
not a form of free radicals. The presence of the 
phospholipase A2 enzyme located in the cell's 
phospholipid membrane results in the formation of 
free-PUFA-OOH which is released into the cytosol. 
Activation of the enzymatic chain consisting of the 
cascade of superoxide dismutase, catalase, and 
glutathione peroxidase converts changes in PUFA-
OOH to hydroxy polyunsaturated fatty acid (PUFA-
OH). Free radical conversion to a stable molecule 
22
showed that Vitamin E has an antioxidant effect.
Besides being able to act as an antioxidant, 
Vitamin E derivatives such as a-Tocopherol also 
have pro-oxidant effects. Because every time the 
anti-oxidative mechanism occurs, a-Tocopherol 
radical will also be formed (a-Toc). Basically the 
pro-oxidative effect that occurs will be suppressed 
by other reactions involving a-Toc and vitamin C  
(L-Ascorbic Acid, Asa). The reduction that involves 
the enzyme Glutathione (GSH) in the cytosol and 
Ubiquinol (UQH2) in the cell membrane acts as the 
next non-oxidative molecule formation. The pro-
oxidant effect on vitamin E provides a new picture of 
the metabolic properties of Vitamin E which turns 
out to have an antagonistic effect with the main 
17
working of this molecule itself.  In certain 
conditions such as increased consumption of vitamin 
E or the presence of defects in GSH and UQH2 
enzymes, it is possible to increase oxidative 
reactions which lead to an increase in free radical 
reactions in the body.  
The results of this study, exposure to low 
doses of vitamin E did not provide a statistically 
significant difference compared to the group 
exposed to cisplatin alone. However, the level of 
damage to the nephrons that occurred between the 
two groups was seen to be greater in the treatment 
group that received cisplatin and a lower dose of 
Vitamin E. In addition, exposure to higher levels of 
vitamin E resulted in a significant degree of nephron 
damage compared to the control group and treatment 
group that exposed to low dose of vitamin E. It 
indicates that exposure to vitamin E in the damaged 
mice kidney will initiate a pro-oxidative mechanism 
and lead to increased progression of kidney damage. 
This might occur because of a disruption of the 
mechanism of transformation residual vitamin E in 
the form of radical a-Tocopherol. Previously 
administered cisplatin exposure might have an effect 
in decreasing the expression of essential cellular 
regulator proteins. The decrease in this protein can 
also occur in GSH and UBQ2 proteins which act as 
reductor a-Toc agents. The result of the previous 
event is the accumulation of -Toc which results in the 
formation of large amounts of free radicals at the 
cellular level.
In addition, in this study the parameters used 
were the changing of kidney tissue assessed from 
histopathological results. The degree of kidney 
damage assessed in this study was observed based on 
the acute and chronic inflammatory responses that 
occur in the tubules and glomerular kidneys. 
Cisplatin administration has been known to cause 
93
nephrotoxicity. This has been proven by observation 
made in this study, which showed an increase in the 
score of kidney damage after exposure of cisplatin. 
Changing in renal histopathological in this study also 
serve as a reference for the effects of vitamin E on 
mice nephrons. The reference of the formation free 
radical in this study is inflammation caused by 
changing of free radical cell. One of the derivates of 
vitamin E is a-Tocopherol, which is able to induce 
the decreasing free radical activity in cells by 
stimulating the formation of hydroxy poly-
unsaturated fatty acid (PUFA-OH). The solubility of 
very low PUFA-OH therefore the phospholipase A2 
(PLA2) enzyme is needed. 
The increasing expression of PUFA-OH will 
automatically result in increasing of PLA2 
expression. In addition to increasing the solubility of 
PUFA-OH, PLA2 also play a role in initiating the 
inflammatory cascade. PLA2 also causes the 
formation of arachidonic acid which later will play 
an important role in the inflammatory response. The 
administration of vitamin E basically will increase 
PUFA-OH and PLA 2 enzymes. This may explain 
the microscopy picture of inflammatory in the 
administration of Vitamin E will result in chronic 
23
inflammation of the tubules and kidneys.
CONCLUSION
There was no significant increase in the 
degree of glomerular and tubular damage in mice 
that received cisplatin and vitamin E exposure at a 
dose of 50 mg/kg compared to glomerular and 
tubular mice that received cisplatin exposure alone, 
but there was an increased degree of glomerular and 
tubular damage in mice that received cisplatin and 
vitamin E exposure at dose of 200 mg/kg compared 
to glomerular and tubular mice that received to 
cisplatin and vitamin E exposure at dose of 50 
mg/kg.
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